Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing.

doi:10.1002/1878-0261.12023

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing.

Molecular oncology - 1 Feb 2017

Schmiegel Wolff, Scott Rodney J, Dooley Susan, Lewis Wendy, Meldrum Cliff J, Pockney Peter, Draganic Brian, Smith Steve, Hewitt Chelsee, Philimore Hazel, Lucas Amanda, Shi Elva, Namdarian Kateh, Chan Timmy, Acosta Danilo, Ping-Chang Su, Tannapfel Andrea, Reinacher-Schick Anke, Uhl Waldemar, Teschendorf Christian, Wolters Heiner, Stern Josef, Viebahn Richard, Friess Helmut, Janssen Klaus-Peter, Nitsche Ulrich, Slotta-Huspenina Julia, Pohl Michael, Vangala Deepak, Baraniskin Alexander, Dockhorn-Dworniczak Barbara, Hegewisch-Becker Susanne, Ronga Philippe, Edelstein Daniel L, Jones Frederick S, Hahn Stephan, Fox Stephen B

Abstract excerpt

An accurate blood-based RAS mutation assay to determine eligibility of metastatic colorectal cancer (mCRC) patients for anti-EGFR therapy would benefit clinical practice by better informing decisions to administer treatment independent of tissue availability. The objective of this study was to determine the level of concordance between plasma and tissue RAS mutation status in patients with mCRC to gauge whether...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged

Share to Colorectal Cancer Treatments and Studies

Share to Colorectal Neoplasms

Share to DNA, Neoplasm

Share to ErbB Receptors

Share to EGFR gene

Share to Genes, ras

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 28106345
DOI: 10.1002/1878-0261.12023
PMCID: PMC5527457

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing.PMID 28106345Read ↗

Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer.Semantic proximity Read ↗

Blood-based RAS mutation testing: concordance with tissue-based RAS testing and mutational changes on progression.Semantic proximity Read ↗

RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial.Semantic proximity Read ↗

Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study.Semantic proximity Read ↗

KRAS and NRAS mutational analysis in plasma ctDNA from patients with metastatic colorectal cancer by real-time PCR and digital PCR.Semantic proximity Read ↗

The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: a noninterventional, uncontrolled multicenter study.Semantic proximity Read ↗

Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patientsSemantic proximity Read ↗

Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for RAS Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study.Semantic proximity Read ↗

Analysis of KRAS mutations in circulating tumor DNA and colorectal cancer tissue.Semantic proximity Read ↗

Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS‐mutant metastatic colorectal cancerSemantic proximity Read ↗

Expanded Low Allele Frequency RAS and BRAF V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial.Semantic proximity Read ↗

Analysis of Circulating Tumor DNA to Confirm Somatic KRAS MutationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.